Psychotropic drugs and CYP2D6 in late-life psychiatric and neurological disorders. What do we know?
2017
ABSTRACTIntroduction: Late-life psychiatric and neurological disorders (LLPND) are interesting models to understand the potential role of pharmacogenetics in drug management, since several pharmacological approaches for treating LLPND have proven to be ineffective or deleterious, thus resulting in therapeutic failures (TF) and adverse drug reactions (ADR). Common variants in the genes encoding the cytochrome P450 (CYP) enzyme system, the ‘engine room’ of drug metabolism, together with well-known age-related increased polypharmacy also contributed to the prevalence of TF and ADR observed in these patients, also rising number and time of hospital readmissions and rate of institutionalizations.Areas covered: The genetics of CYP and how it may be used for the management of the outcomes of the most frequent drugs (antidepressants, antipsychotics, anticholinesterase inhibitors, and anxiolytics) used in LLPND.Expert opinion: Tailored CYP-based pharmacological treatments of LLPND will reduce TFs and ADRs, improvi...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
158
References
6
Citations
NaN
KQI